Edition:
United States

Astellas Pharma Inc (4503.T)

4503.T on Tokyo Stock Exchange

1,398JPY
10:29pm EDT
Change (% chg)

¥-6 (-0.39%)
Prev Close
¥1,404
Open
¥1,403
Day's High
¥1,406
Day's Low
¥1,398
Volume
2,095,600
Avg. Vol
8,070,024
52-wk High
¥1,779
52-wk Low
¥1,396

Latest Key Developments (Source: Significant Developments)

Astellas Pharma unit to sell Astellas Pharma Technologies to Avara
Thursday, 4 Aug 2016 02:00am EDT 

Astellas Pharma Inc <4503.T>: Says its unit to sell Astellas Pharma Technologies, Inc. to Avara Norman Pharmaceutical Services, Inc (Avara) on Aug. 4 (U.S time) .Says transaction price is not disclosed.  Full Article

Astellas to transfer U.S. manufacturing unit to Avara
Wednesday, 3 Aug 2016 08:52pm EDT 

Astellas Pharma Inc <4503.T> : Astellas announces transfer of U.S. manufacturing subsidiary to Avara . Under terms of transaction, APT employees will remain employed at site .Astellas Pharma Technologies, Inc. will be renamed Avara Pharmaceutical Technologies, Inc.  Full Article

Astellas to transfer U.S. manufacturing unit to Avara<4503.T>
Wednesday, 3 Aug 2016 07:00pm EDT 

Astellas Pharma Inc <4503.T> : Astellas announces transfer of U.S. manufacturing subsidiary to Avara . Under terms of transaction, APT employees will remain employed at site .Astellas Pharma Technologies, Inc. will be renamed Avara Pharmaceutical Technologies, Inc.  Full Article

Cytokinetics, Astellas announce option right for Tirasemtiv
Wednesday, 27 Jul 2016 07:30am EDT 

Cytokinetics Inc : Cytokinetics and Astellas announce option right for Tirasemtiv and expansion of global collaboration for CK-2127107 in ALS . Option has potential for more than $100 million in payments associated with exercise of option . To receive $65 million in upfront payments, $30 million in additional sponsored research and development .Companies to extend joint research focused on discovery of skeletal muscle activators through 2017.  Full Article

Shionogi and Astellas Pharma looking to sell drug brands that have lost patent protection - Nikkei<4503.T><4507.T>
Monday, 4 Jul 2016 04:34pm EDT 

Nikkei: Shionogi and Astellas Pharma are looking to sell off drug brands that have lost patent protection - Nikkei . Shionogi could select buyers at the end of July; proceeds from the sales estimated at nearly 20 billion yen - Nikkei . Astellas could receive up to 50 billion yen by divesting several drugs - Nikkei .  Full Article

Medivation and Astellas initiate Phase III trial of enzalutamide
Thursday, 2 Jun 2016 07:00am EDT 

Medivation Inc : Astellas and Medivation initiate Phase III trial of enzalutamide in patients with triple-negative breast cancer .Trial, which will be led by Medivation, is expected to begin patient enrollment in Q4 of 2016.  Full Article

Astellas Pharma to retire 68 mln treasury shares
Tuesday, 10 May 2016 11:05pm EDT 

Astellas Pharma Inc <4503.T>: Says it will retire 68 million shares (3.1 percent stake) of its common stock on June 20 .Says the total shares outstanding will be 2.15 billion shares after the retirement.  Full Article

Astellas to retire treasury stock equivalent to 3.06 pct of shares outstanding
Tuesday, 10 May 2016 11:03pm EDT 

Astellas Pharma Inc <4503.T>: to retire treasury stock equivalent to 3.06 percent of shares outstanding on June 20 Further company coverage: [4503.T].  Full Article

Astellas Pharma and LEO Pharma close transaction to transfer global dermatology business
Thursday, 31 Mar 2016 08:00pm EDT 

Astellas Pharma Inc:Says the company and LEO Pharma A/S completed the relevant closing conditions on March 31 to allow the transfer of the Astellas’ global dermatology business to LEO Pharma on April 1.Says on Nov. 11, 2015, Astellas and LEO Pharma entered into an Asset Purchase Agreement with regard to Astellas’ global portfolio of dermatology products, which includes the eczema treatment Protopic® (except for in Japan), and other products for the treatment of acne and skin infections.Astellas and LEO Pharma have now satisfied the pre-agreed conditions to close the transaction, with Astellas having received €675 million as a result.  Full Article

Astellas Pharma announces phase III trial of enzalutamide initiated in metastatic hormone sensitive prostate cancer
Thursday, 24 Mar 2016 09:00pm EDT 

Astellas Pharma Inc:Says the ARCHES phase III trial for enzalutamide with androgen deprivation therapy (ADT) versus placebo with ADT in metastatic hormone sensitive prostate cancer (mHSPC) patients, has been initiated.Says ARCHES means AR Inhibition with ChemoHormonal Therapy in Men with MEtastatic Castrate Sensitive Prostate Cancer.  Full Article

More From Around the Web

BRIEF- Astellas Pharma completes acquisition of Ogeda SA in Belgium

* Says it has completed the acquisition of Ogeda SA, a drug discovery company located in Gosselies, Belgium, and Ogeda has become a wholly owned subsidiary of the company as of CET May 17